Oncology
Targeted therapies and biosimilars for cancer care.
Oncology is a strategic growth priority for Al Sumo. Iraq's demand for modern cancer therapies — including targeted treatments and biosimilars — continues to grow, supported by national oncology centers and expanding hospital capacity.
Market outlook
Growing national investment in oncology centers and hospital-based cancer care is increasing demand for quality-assured oncology portfolios, including biosimilars.
Partner opportunities
We are actively seeking partners with oncology and biosimilar portfolios who require experienced regulatory navigation, cold-chain handling, and hospital-channel access in Iraq.
Current portfolio categories
- Targeted therapies
- Biosimilars
- Supportive care
- Hospital-grade injectables
Scientific & commercial support
- Scientific detailing by trained medical representatives
- KOL engagement and advisory boards
- Regulatory registration and lifecycle management
- GDP-aligned warehousing and cold chain
- Nationwide distribution across 18 governorates
- Tender participation and hospital access
The information on this website is intended for general corporate and educational purposes. It does not replace professional medical advice, diagnosis, or treatment.